BIIB Valuation

Biogen Inc

Add to Watchlist

Advanced Chart

127.850

+5.17(4.214%)1D

Overview
Forecast
Valuation
Earnings

BIIB Relative Valuation

BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIIB is overvalued; if below, it's undervalued.

Historical Valuation

Biogen Inc (BIIB) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.84 is considered Undervalued compared with the five-year average of 14.09. The fair price of Biogen Inc (BIIB) is between 189.09 to 278.05 according to relative valuation methord. Compared to the current price of 127.85 USD , Biogen Inc is Undervalued By 32.39%.

Relative Value

Fair Zone

189.09-278.05

Current Price：127.85

32.39%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.05

P/B

Median3y

2.24

Median5y

2.81

13.30

FCF Yield

Median3y

6.00

Median5y

7.39

Competitors Valuation Multiple

The average P/S ratio for BIIB's competitors is 10.03, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of 2.02, which is -79.89% above the industry average. Given its robust revenue growth of 6.13%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap